Australia’s Therapeutic Goods Administration (the equivalent of the U.S. Food and Drug Administration) has restricted the use of Risperdal due to increased risks of strokes in patients. The TGA cited a study which found patients being treated with Risperdal for dementia other than Alzheimer’s were more than twice as likely to suffer from cerebrovascular events (strokes).
Some doctors have expressed increased concern over Risperdal side effects after several studies have linked the drug to various conditions, including gynecomastia in boys and male adolescents. Gynecomastia is the development of breast tissue, a condition that comes from increased levels of the hormone prolactin and often requires surgery to correct.
Risperdal manufacturer Janssen Pharmaceuticals along with parent company Johnson & Johnson currently face multiple Risperdal lawsuits alleging that the drug caused breast growth in young boys. The company has recently been ordered to pay millions to patients who developed breasts after being given the drug to treat bipolar disorder and symptoms of ADHD.